Skip to content

Zymeworks ZYME Total Equity

Total Equity at other companies

Pfizer logo
PfizerPFE
$90.1B-0.3%
Amgen logo
AmgenAMGN
$9.19B+48.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$12.75M-62.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$938.08M-8.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$636.01M+5.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$394.88M+12.8%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's total equity?
Zymeworks (ZYME) reported total equity of $163.59M in Q1 2026.
How has Zymeworks's total equity changed year-over-year?
Zymeworks's total equity decreased by 49.7% year-over-year, from $324.97M to $163.59M.
What is the long-term trend for Zymeworks's total equity?
Over 5 years (2020 to 2025), Zymeworks's total equity has grown at a -8.1% compound annual growth rate (CAGR), from $409.92M to $268.5M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.